Zaman Faruquz, Bach Christian, Junaid Islam, Papatsoris Athanasios G, Pati Jhumur, Masood Junaid, Buchholz Noor
Department of Urology, Barts and the London NHS Trust, London, UK.
Curr Urol. 2012 May;6(1):1-7. doi: 10.1159/000338861. Epub 2012 Apr 30.
Benign prostatic hyperplasia (BPH) and cataract formation are common in older people. Medical management of symptomatic BPH is often preferred to surgical treatment as surgery increases the risk of morbidities, whereas, surgery is the main form of treatment to restore sight in patient with cataract. The clinical treatment of BPH is either alpha-1 adrenergic antagonist alone or combination of alpha reductase inhibitor and alpha adrenergic receptor (AR) antagonist. There are four alpha-AR antagonists currently available to treat BPH. The uroselective alpha-blocker tamsulosin is the most commonly used drug among all. Studies showed that the majority of the patients who develop intraoperative floppy iris syndrome (IFIS) were on tamsulosin. Women are more likely to develop cataract than men and some recent studies showed that tamsulosin is effective in treating female lower urinary tract symptoms and thereby can cause IFIS during cataract surgery.
We performed a critical review of the published articles and abstracts on association of IFIS with alpha-blockers and other medications as well as other medical conditions.
Tamsulosin is the most common cause of formation of IFIS. However, not all patients given tamsulosin develop IFIS and cases have been reported without any tamsulosin treatment.
Tamsulosin is a recognized cause to impede mydriasis and lead to IFIS during cataract surgery. Urologist should collaborate with their ophthalmology colleagues and general practitioner during prescribing tamsulosin in patients with history of cataract or waiting for planned cataract surgery. The increasing life expectancy and growth of older people will increase the number of men and women who suffer from lower urinary tract symptoms as well as cataract. Therefore, further research and studies are required to properly understand the relation of alpha blockers and IFIS.
良性前列腺增生(BPH)和白内障形成在老年人中很常见。有症状的BPH通常首选药物治疗而非手术治疗,因为手术会增加发病风险,而手术是恢复白内障患者视力的主要治疗方式。BPH的临床治疗要么单独使用α-1肾上腺素能拮抗剂,要么联合使用α还原酶抑制剂和α肾上腺素能受体(AR)拮抗剂。目前有四种α-AR拮抗剂可用于治疗BPH。在所有药物中,尿选择性α阻滞剂坦索罗辛是最常用的药物。研究表明,大多数发生术中虹膜松弛综合征(IFIS)的患者正在服用坦索罗辛。女性比男性更容易患白内障,最近的一些研究表明,坦索罗辛在治疗女性下尿路症状方面有效,从而可能在白内障手术期间导致IFIS。
我们对已发表的关于IFIS与α阻滞剂及其他药物以及其他医疗状况之间关联的文章和摘要进行了批判性综述。
坦索罗辛是IFIS形成的最常见原因。然而,并非所有服用坦索罗辛的患者都会发生IFIS,也有未接受任何坦索罗辛治疗却出现该症状的病例报道。
坦索罗辛是白内障手术期间阻碍瞳孔散大并导致IFIS的公认原因。泌尿科医生在为有白内障病史或等待计划中的白内障手术的患者开坦索罗辛时,应与眼科同事和全科医生合作。预期寿命的增加和老年人口的增长将使患有下尿路症状以及白内障的男性和女性数量增加。因此,需要进一步的研究来正确理解α阻滞剂与IFIS之间的关系。